Verastem Past Earnings Performance
Past criteria checks 0/6
Verastem has been growing earnings at an average annual rate of 9.9%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 33.4% per year.
Key information
9.9%
Earnings growth rate
37.5%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -33.4% |
| Return on equity | -111.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Verastem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -87 | 31 | 61 |
| 30 Sep 23 | 0 | -77 | 28 | 50 |
| 30 Jun 23 | 0 | -75 | 27 | 47 |
| 31 Mar 23 | 0 | -73 | 26 | 49 |
| 31 Dec 22 | 3 | -74 | 25 | 51 |
| 30 Sep 22 | 3 | -73 | 25 | 51 |
| 30 Jun 22 | 3 | -78 | 24 | 49 |
| 31 Mar 22 | 4 | -73 | 24 | 44 |
| 31 Dec 21 | 2 | -71 | 24 | 39 |
| 30 Sep 21 | 2 | -75 | 26 | 38 |
| 30 Jun 21 | 81 | -39 | 38 | 40 |
| 31 Mar 21 | 84 | -45 | 47 | 39 |
| 31 Dec 20 | 89 | -68 | 59 | 41 |
| 30 Sep 20 | 92 | -87 | 75 | 43 |
| 30 Jun 20 | 22 | -130 | 80 | 45 |
| 31 Mar 20 | 21 | -149 | 93 | 46 |
| 31 Dec 19 | 17 | -149 | 101 | 46 |
| 30 Sep 19 | 15 | -122 | 104 | 42 |
| 30 Jun 19 | 22 | -113 | 107 | 41 |
| 31 Mar 19 | 28 | -89 | 93 | 42 |
| 31 Dec 18 | 27 | -72 | 77 | 44 |
| 30 Sep 18 | 26 | -79 | 58 | 46 |
| 30 Jun 18 | 10 | -81 | 38 | 52 |
| 31 Mar 18 | 0 | -76 | 26 | 49 |
| 31 Dec 17 | 0 | -68 | 21 | 46 |
| 30 Sep 17 | 0 | -61 | 19 | 42 |
| 30 Jun 17 | 0 | -46 | 18 | 29 |
| 31 Mar 17 | 0 | -41 | 18 | 24 |
| 31 Dec 16 | 0 | -36 | 17 | 20 |
| 30 Sep 16 | 0 | -37 | 17 | 21 |
| 30 Jun 16 | 0 | -44 | 17 | 28 |
| 31 Mar 16 | 0 | -51 | 17 | 34 |
| 31 Dec 15 | 0 | -58 | 18 | 41 |
| 30 Sep 15 | 0 | -60 | 18 | 43 |
| 30 Jun 15 | 0 | -58 | 18 | 40 |
| 31 Mar 15 | 0 | -55 | 18 | 38 |
| 31 Dec 14 | 0 | -53 | 18 | 35 |
| 30 Sep 14 | 0 | -51 | 17 | 34 |
| 30 Jun 14 | 0 | -48 | 17 | 31 |
| 31 Mar 14 | 0 | -45 | 16 | 29 |
| 31 Dec 13 | 0 | -41 | 15 | 26 |
| 30 Sep 13 | 0 | -38 | 16 | 22 |
Quality Earnings: 0LOV is currently unprofitable.
Growing Profit Margin: 0LOV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0LOV is unprofitable, but has reduced losses over the past 5 years at a rate of 9.9% per year.
Accelerating Growth: Unable to compare 0LOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0LOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0LOV has a negative Return on Equity (-111.25%), as it is currently unprofitable.